China Stops Sales Of OTC Pediatric Drugs Containing Amantadine
This article was originally published in PharmAsia News
Executive Summary
China’s State FDA has recently forbidden the use of three top-selling OTC pediatric compounds containing amantadine for infants under the age of 1 for safety and efficacy reasons.
You may also be interested in...
Scotland's MGB Plots Phase III For Promising Antibacterial
With a late-stage compound on its hands, MGB is currently in discussions with several biotech and pharma companies and also with venture capitalists to continue late-stage development of a novel antibiotic which could transform treatment of Clostridium difficile.
AstraZeneca Vaccine May Only Gain EU Approval In Under 70s
AZ and the EU are at loggerheads over supplies of the COVID-19 vaccine. On top of that, its marketing authorization will present dilemmas.
Moment Of Truth In EU For Amarin’s ‘Multi-Billion-Dollar Opportunity’ Drug
The European Medicines Agency is expected to decide soon whether Amarin’s fish oil pill, Vascepa, should win pan-EU marketing approval for reducing cardiovascular risk.
Need a specific report? 1000+ reports available
Buy Reports